Presentation is loading. Please wait.

Presentation is loading. Please wait.

Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between.

Published byRoy Douglas Modified over 5 years ago

Similar presentations

Presentation on theme: "Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between."— Presentation transcript:

1 Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between initial and final CEA-specific T-cell responses in HLA-A2 positive patients (Y axis). Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between initial and final CEA-specific T-cell responses in HLA-A2 positive patients (Y axis). Margaret von Mehren et al. Clin Cancer Res 2001;7: ©2001 by American Association for Cancer Research

Download ppt "Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between."

Similar presentations

The expression and signaling of FGFR3 in WM cells.

The expression and signaling of FGFR3 in WM cells.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.
Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
Frequency of patients in flare at each time point over 3 months

Frequency of patients in flare at each time point over 3 months
Distribution of informative SNPs with LOH (black bars) on each chromosome (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome)

Distribution of informative SNPs with LOH (black bars) on each chromosome (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome)
Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors. Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors.

Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors. Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors.
Correlation between MRP1 mRNA expression and CF efflux-blocking factors of MK-571 (A) and between MDR1 mRNA expression and Rh123 efflux-blocking factors.

Correlation between MRP1 mRNA expression and CF efflux-blocking factors of MK-571 (A) and between MDR1 mRNA expression and Rh123 efflux-blocking factors.
T-cell phenotypes of cells harvested from the peripheral blood of patients undergoing chemotherapy. T-cell phenotypes of cells harvested from the peripheral.

T-cell phenotypes of cells harvested from the peripheral blood of patients undergoing chemotherapy. T-cell phenotypes of cells harvested from the peripheral.
Performance and potency comparisons of qHTS runs.

Performance and potency comparisons of qHTS runs.
A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.
Protein expression profile in a dasatinib-resistant cell line.

Protein expression profile in a dasatinib-resistant cell line.
Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+

Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+
CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.
Matriptase-2 inhibited breast tumor development in vivo.

Matriptase-2 inhibited breast tumor development in vivo.
Effect of nicotinamide and carbogen on 5-FU uptake (measured as SUV3

Effect of nicotinamide and carbogen on 5-FU uptake (measured as SUV3
Pre- and post-vorinostat values of ER-related gene expression using the Oncotype DX 21-gene assay. Pre- and post-vorinostat values of ER-related gene expression.

Pre- and post-vorinostat values of ER-related gene expression using the Oncotype DX 21-gene assay. Pre- and post-vorinostat values of ER-related gene expression.
Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Similar presentations

Ads by Google